0.33%

Gold vs US Dollar

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

GSK Gsk Plc

1,644.50

4.00 (0.24%)

Last Updated: 15:45:59

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Gsk Plc	LSE:GSK	London	Ordinary Share	GB00BN7SWP63	ORD 31 1/4P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	4.00	0.24%	1,644.50	1,644.50	1,645.00	1,647.50	1,634.00	1,638.50	1,415,048	15:45:59

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	30.33B	4.93B	1.1970	13.70	67.52B

Genmab 1Q Sales of Arzerra Leukaemia Drug at GBP11.1 Million

06/05/2015 12:58pm

Dow Jones News

Gsk (LSE:GSK)
Historical Stock Chart

From Apr 2019 to Apr 2024

   By Dominic Chopping

Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of the Arzerra (ofatumumab) treatment for chronic lymphocytic leukaemia by GlaxoSmithKline PLC (GSK) and Novartis AG (NVS) during the first quarter of 2015 were GBP11.1 million.

This figure consists of net sales in the U.S. of GBP6.0 million and in the rest of the world of GBP5.1 million.

Under the terms of the collaboration with Novartis Pharma AG, Genmab expects to receive a royalty payment of approximately DKK22 million.

Arzerra is marketed under a co-development and collaboration agreement between Genmab and Novartis, who acquired an interest in the drug from GSK earlier this year.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires